Related Experiment Video
Updated: Aug 15, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Antibodies against erythropoietin and other protein-based therapeutics: an overview
Arno Kromminga1, Huub Schellekens
1Institute for Immunology, Clinical Pathology, Molecular Medicine, Lademannbogen 61, 22339 Hamburg, Germany. arno.kromminga@gmx.de
Abstract:
Many factors influence the immunogenicity of protein-based therapeutics. At present, it is inconceivable to manufacture a biopharmaceutical without the risk of this adverse effect. Thus, the detection and characterization of antibodies against protein-based therapeutics is a significant task. Only clinical studies and careful monitoring of the market can be used to conclusively demonstrate rates of immunogenicity in humans for protein therapeutics. Fully validated, reliable, and robust in vitro assays, in combination with sensitive bioassays, should be used to address these topics.
Related Concept Videos
Cross-reactivity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Erythropoiesis
Erythropoiesis
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Inhibitors of Viral Protein Synthesis

